Introduction
Psoriasis is a chronic autoimmune skin condition that affects ≈8 million Americans [1] . Approximately 10% of affected Americans have moderate-to-severe psoriasis that necessitates use of phototherapy or systemic medications, yet many patients remain undertreated [2, 3] . According to a survey undertaken by the National Psoriasis Foundation in 2001, 40% of respondents felt frustrated with the ineffectiveness of therapies, and 32% felt that treatment was not sufficiently aggressive [4] .
Biologic medications ("biologics") have revolutionized the management of psoriasis. Biologic agents target specific steps in the immune pathways that lead to psoriasis [5] . Biologics are not metabolized by the cytochrome P450 system, so druginteraction problems are limited [6] . In addition, compliance with treatment using biologics, though not perfect, is higher than that observed with other psoriasis medications (e.g. topical agents, phototherapy) [6] . Biologics are expensive, but the cost is offset by: significant reductions in the number of hospital stays; use of other systemic therapies; improved Psoriasis Area and Severity Index (PASI) outcomes; and increased satisfaction by patients [7, 8] .
There are two main categories of biologic treatments for psoriasis: tumor necrosis factor (TNF)-α inhibitors (e.g. etanercept, adalimumab) and interleukin-12/23 inhibitors (e.g. ustekinumab). Cost analyses of these drugs have yielded estimates from $7,993 a year to $48,000 a year [9] [10] [11] . Given these high sums, cost is an important consideration for physicians and patients before choosing a biologic agent. Here, we provide an updated estimate of the annual cost of etanercept, adalimumab, and ustekinumab, and review the literature regarding cost analyses pertinent to these drugs. We also discuss the growing role of cost-effectiveness in treatment guidelines.
Methods

Annual drug costs
Annual drug costs were estimated for etanercept, adalimumab, and ustekinumab. [13] . For adalimumab, the cost estimate consisted of an 80-mg loading dose, followed by 40 mg every other week beginning one week after the initial dose [14] . For ustekinumab, recommended treatment doses differ depending on patient weight (≤100 kg or >100 kg). Consequently, a patient weight of 80 kg was assumed. The annual cost estimate included a dose of 45 mg at 0-and 4-weeks, and 45 mg every 12 weeks thereafter [15] .
A trend of drug costs from 2004 to 2014 was calculated using the AWP/unit specific to each year listed in Red Book Drug Topics for each drug. Annual cost was then estimated using the same treatment paradigm as outlined above. In addition, the percentage change in annual cost was calculated, and compared with overall annual inflation and annual healthcare inflation.
Estimation of "sales-based cost"
Wholesale prices may not provide an accurate measure of what payers are paying for biologics because prices may be modified by contract issues. To estimate cost after accounting for drug discounting, a sales-based estimate of cost for a biologic drug for psoriasis was calculated using the following formula:
Sales-based cost of drugs = gross US sales ($) total number of patients treated Gross sales in the US were appraised through the 2013 Securities and Exchange Commission 10K Annual Reports for Amgen and Abbvie, the producers of etanercept and adalimumab, respectively [16, 17] . Sales of ustekinumab were monitored through annual sales and earnings reports for Johnson and Johnson [18] .
A direct estimate of the total number of patients taking each drug was not available. To estimate the total number of patients taking each drug, we used prescription data available on the Bloomberg L.P. database to determine the total number of prescriptions (refills and new) from 2011 to 2013. The total number of prescriptions (refills and new) each year was divided by two based on the assumption that each psoriasis patient receives two prescriptions a year for biologic agents. Information from the database is derived from Symphony Health Solutions (provider of data on prescription audits in the US). It provides information on weekly and monthly retail, non-retail, and mail-order prescription activity. The average annual rate of increase was of the same order of magnitude for all three drugs: 8.2% for etanercept, 9.2% for adalimumab, and 11.0% for ustekinumab ( Figure 2 ). Costs were calculated using an AWP specific to each year for each drug. Annual costs were based on recommended treatment paradigms and represent the first year of treatment (includes loading doses). AWP, average wholesale price.
Results
Expected annual costs for biologic drugs
These rates of increase were higher than the overall inflation rate of 1.5% and the overall healthcare inflation rate of 2.5% [19, 20] .
Sales-based cost of drugs
Our sales-based cost of drugs was lower than published wholesale cost rates, which may reflect the effects of contracting (as was anticipated; Table 2 ). Sales-based cost in 2013 was greatest for ustekinumab ($25,012), followed by adalimumab and etanercept, which were priced similarly at $6,786 and $6,629, respectively ( 
Discussion
The cost of one year of induction and maintenance treatment was highest for ustekinumab ($53,909), followed by etanercept ($46,395), and adalimumab ($39,041). These estimates are considerably higher compared with previous estimates: $7,993 to $48,731 per year for etanercept, $19,000 to $37,000 for adalimumab, and $15,243 to $34,951 for ustekinumab [1, [9] [10] [11] [21] [22] [23] [24] . These differences may be attributable to: differences in treatment paradigms; variations in valuation methodology; increases in the AWP of drugs over time. For example, some studies included the cost of laboratory tests and office visits [1, 9, 10, 21, 23] , and used the wholesale acquisition price for drug costs [25, 26] . The AWP is typically set 20-25% above the wholesale acquisition cost or list price [27] . These studies were conducted several years ago and our calculations suggest that the AWP increased over time, especially for ustekinumab (>50% over five years). Hence, it is likely that our higher estimate is also due to a rising AWP.
Inflation could be another potential cause for the higher costs estimated in this analysis. However, our calculated increases in cost clearly outstrip the increase in Consumer Price IndexUrban for overall and healthcare-specific inflation -a finding that echoes the work of Beyer et al. [22] . Other factors that may be responsible (at least in part) for rising costs include: increasing costs for research and development; costs of subject recruitment; increasing competition in the market for drugs with similar efficacies; increasing safety regulation (which translates into longer and more complicated clinical trials) [28] . Biologic agents are also more complicated to produce compared with more "traditional" therapies [22] . A review of cost-effectiveness studies on biologic agents in psoriasis yielded inconsistent results for the most cost-effective agent (Supplemental Table 1 ), probably because different patient cohorts and agents were studied [9] [10] [11] 21, 23, 25, 26, [32] [33] [34] [35] . Conclusions drawn from were written. However, since then, favorable five-year safety data have been reported [31] . In contrast, treatment guidelines from the American Academy of Dermatology in 2011 for moderate-to-severe psoriasis do not specify the sequence by which biologics should be prescribed. cost-effectiveness models should be interpreted with caution because they rely on data drawn from idealized conditions for randomized controlled trials, a study period of 12 weeks, and drug prices that may not reflect the contracted price of the drug paid by insurers.
Supplemental
Our cost analysis had several limitations. First, other direct costs, such as physician visits, laboratory tests, and treatment for adverse events, were not included. However, they are likely to have been minimal compared with the cost of biologic drugs. Indirect costs (including comorbidities and increased mortality with severe psoriasis) are also important considerations. However, we could not measure these costs, so they were not included in this therapeutics-specific analysis. Second, in our estimate of the sales-based cost according to the total number of patients treated with biologic drugs, we assumed that patients fill two prescriptions each year, but this "ballpark estimate" may not reflect true prescribing patterns. Lastly, our estimate of sales-based cost does not reflect the specific contracts and prices of the insurers of individual patients. Thus, if choosing a therapy for a specific patient, then estimates of which drug is the most expensive may not apply because we do not know that contracted drug-purchasing rates of the insurer. We did not have access to insurance databases in this study, but using data from these sources may be helpful in future studies.
Psoriasis is a chronic, long-term condition, so awareness of treatment costs is important. Our cost analysis demonstrates that the annual cost of drugs is expensive and continues to increase each year. New oral therapies on the market may provide less costly alternatives. For example, apremilast, an inhibitor of phosphodiesterase-4 approved by the Food and Drug Administration in March 2014 for psoriatic arthritis, costs $27,375 a year based on wholesale pricing of a dose of 30 mg twice a day. However, with a lower efficacy rate, it may not be more cost-effective [10] . Tofacitinib, an inhibitor of JAKkinase -if used for psoriasis at 5 mg twice a day -would cost $32,000 a year based on wholesale prices [12] . It is hoped that "biosimilars" will lower the cost of biologic agents. However, biosimilars are anticipated to cost only 20-30% less than branded biologics -a less drastic reduction in cost compared to generics which, at least in the past, lowered prices ≤90% and captured a large share of the market [36] . As a significantly low-cost, highly effective, safe alternative to biologics for patients who have failed conventional therapy is not on the horizon, costs will continue to play a part in the choice of therapy for severe psoriasis.
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